Brief: Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018
06/10/2025 13:09
Oct 6 (Reuters) - Alvotech SA ALVO.O: KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB) Source text: ID:nBwblfJYra Further company coverage: ALVO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm